Neurocognition After Radiotherapy in CNS- and Skull-base Tumors (NARCiS)
Cognition, Brain Tumor, Magnetic Resonance Imaging
About this trial
This is an interventional diagnostic trial for Cognition
Eligibility Criteria
Inclusion Criteria: Adult patients (≥ 18 years at the time of diagnosis) with a primary brain or base of skull tumour, who are amenable for conventionally fractionated radiotherapy (photon or proton irradiation) Exclusion Criteria: Patients with tumours with poor prognostic characteristics (e.g. IDH1/2 wild type glioma, grade III meningioma, H3K27M midline glioma) Patients with tumours requiring craniospinal irradiation (CSI)/whole ventricular irradiation (WVI) Hypofractionated/stereotactic radiation (fraction sizes > 2 Gy per fraction) Inability to perform the cognitive tests or self-report inventories because of motor/sensory deficits or insufficient Dutch language proficiency Mental retardation documented before diagnosis Pre-diagnosis/pre-existing psychiatric diagnosis resulting in cognitive deficits like psychoses, neurodevelopmental disorders (autism/learning disorders) Relapse priory treated by chemo and/or radiation therapy Genetic syndrome (e.g. Down) Unable to perform MR imaging (claustrophobia, metallic implants like pacemaker/ICD/neurostimulator)
Sites / Locations
- University Hospitals GhentRecruiting
- UZ LeuvenRecruiting
- Gasthuis Zusters AntwerpenRecruiting
Arms of the Study
Arm 1
Other
Primary brain and skull-base tumors
Primary brain and skull-base tumors who are amenable for radiotherapy (photon or proton therapy) will all be examined with neurocognitive tests, questionnaires and advanced MR imaging